BIO-PATH HOLDINGS, INC. (BPTH) Form 10-Q — May 20, 2026
Bio-Path Holdings reported a net loss of $270,000 for the quarter ended March 31, 2026, with only $12,000 in cash remaining. The company has instituted a company-wide operational pause, furloughed most employees, and paused clinical trials due to severe capital constraints. The filing includes a going-concern warning, stating that available cash is insufficient to fund operations for the next 12 months. Additionally, the report was not reviewed by an independent auditor, and management disclosed that internal controls were not effective.
Key figures
- Revenue
- 0
- Total Debt
- 511000
- Cash Position
- 12000
- Shares Outstanding
- 50297451
- Total assets
- 677000
- Total liabilities
- 9163000
- Warrant liability
- 12000
- Rd expense q1 2026
- 38000
- Accumulated deficit
- 126445000
- Gna expense q1 2026
- 259000
- Default penalty rate
- 150%
- Derivative liability
- 462000
- Default interest rate
- 22%
- Promissory note principal jan 2026
- 77000
- Promissory note principal april 2025
- 161000
Price after filing
Close on the filing date to close N calendar days later (from $0.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.